Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
Exon-skipping approach boosts levels of key Rett syndrome protein
Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.
Frameshift: How Caitlin Vander Weele made science communication her business
Her favorite part of research was talking about it. So she left academia and turned that passion into a successful company.
Frameshift: How Caitlin Vander Weele made science communication her business
Her favorite part of research was talking about it. So she left academia and turned that passion into a successful company.
Signs of aging vary across brain cells
Senescence presents differently depending on the cell type, toxic trigger and neighboring cells, two new studies find.
Signs of aging vary across brain cells
Senescence presents differently depending on the cell type, toxic trigger and neighboring cells, two new studies find.